$14.05 0.00 (0%)
2/10/2012 4:00 PM

Dendreon Corp (NASDAQ:DNDN)

CAPS Rating: 2 out of 5

A biotechnology company focused on the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer.

Results 1 - 20 of 350 : 1 2 3 4 5 6 7 8 9 10 Next »

Recs

0
Member Avatar neilepi (82.77) Submitted: 1/15/2012 1:15:23 PM : Outperform Start Price: $14.26 DNDN Score: -4.76

Consensus seems positive and looking at the graph there is more white space above than below...

Recs

0
Member Avatar crubik (45.20) Submitted: 1/8/2012 5:29:19 PM : Outperform Start Price: $12.90 DNDN Score: +3.94

The stock had been much higher in previous years, then was thrashed because of a delay in the release of a prostate cancer medication. The stock fell violently overnight and I think it will stabilize in the next few years. Even if it only regains half of it's previous value, it is a winner.

Recs

1
Member Avatar benyboy (< 20) Submitted: 1/6/2012 3:33:38 AM : Outperform Start Price: $11.48 DNDN Score: +17.53

After this quarter results the company should be able to beat the market...

Recs

0
Member Avatar Chemdawg (96.45) Submitted: 1/5/2012 2:13:01 PM : Outperform Start Price: $10.42 DNDN Score: +29.86

now that the reimbursement issues have been cleared, there is a good chance that DNDN will see 20 per share within the next 12 months. Provenge is extremely expensive and there is only one place to get it..come and get it...or die..its up to you..

Recs

0
Member Avatar portefeuille (99.81) Submitted: 12/23/2011 5:06:06 AM : Outperform Start Price: $7.49 DNDN Score: +81.24

There are currently 1100 DNDN shares in my "fund" with break-even of around 6.81 USD.
http://caps.fool.com/Blogs/fund-trades/678775.

Recs

1
Member Avatar xserver (98.82) Submitted: 11/27/2011 5:28:58 PM : Outperform Start Price: $10.66 DNDN Score: +19.07

Admittedly ignorant about biotechs. So, that is why it is here and not in my real portfolio.

Recs

4
Member Avatar DarthMaul09 (97.90) Submitted: 11/4/2011 11:39:56 PM : Underperform Start Price: $9.11 DNDN Score: -34.92

Medication formularies are more likely to contract as profit margins for insurance companies fall. Independent of how potentially beneficial a new drug may initially appear, there will be a slow acceptance of any treatment that cannot compete on the basis of cost. In this environment their best hope is that their stock price continues to fall to a level where a larger pharm company buys them out for their patents. This may help some of the people that work for the company but it won't help the investors.

Recs

0
Member Avatar Azurik (< 20) Submitted: 11/2/2011 12:35:25 PM : Outperform Start Price: $10.22 DNDN Score: +29.22

DNDN will outperform as Provenge becomes the blockbuster it should have been, once reimbursement program is clear to doctors.

Recs

1
Member Avatar Paigowpete (< 20) Submitted: 10/13/2011 6:35:33 PM : Outperform Start Price: $10.00 DNDN Score: +30.29

Sales should improve dramatically--medicare approved, centers set,reached their goal on centers and everything should follow--earnings growth will follow

Recs

0
Member Avatar Bioyou (< 20) Submitted: 9/30/2011 12:33:31 PM : Outperform Start Price: $9.32 DNDN Score: +33.70

NO.......

Recs

0
Member Avatar acts20 (85.36) Submitted: 9/28/2011 12:06:55 PM : Outperform Start Price: $9.34 DNDN Score: +35.99

oversold.....

Recs

0
Member Avatar ryanman000 (97.40) Submitted: 8/31/2011 3:46:45 PM : Outperform Start Price: $12.30 DNDN Score: +4.48

Time machine investment
Counterpoint: 700% share dilution

Recs

0
Member Avatar daithelacha (< 20) Submitted: 8/31/2011 7:52:59 AM : Underperform Start Price: $12.20 DNDN Score: -5.45

The price is too high.

Recs

0
Member Avatar chopchop0 (75.24) Submitted: 8/19/2011 10:03:27 AM : Outperform Start Price: $12.04 DNDN Score: -0.71

The product is good. The marketing needs work

Recs

2
Member Avatar TMFRisingStars (48.42) Submitted: 8/15/2011 2:05:25 PM : Outperform Start Price: $12.28 DNDN Score: +2.54

Here's the buy rec:
http://www.fool.com/investing/high-growth/2011/08/10/rising-star-buy-digging-dendreon.aspx

Recs

0
Member Avatar jerryguru69 (60.10) Submitted: 8/11/2011 9:23:54 PM : Outperform Start Price: $10.37 DNDN Score: +22.01

they have an individual treatment for prostrate cancer? seriously? yeah, $93k per mo, but a real individual cure? really? it works?

Recs

0
Member Avatar surabayajhonny (89.91) Submitted: 8/10/2011 5:24:41 PM : Outperform Start Price: $10.14 DNDN Score: +19.93

Jim Mueller

Recs

0
Member Avatar AKHENATENX (39.78) Submitted: 8/9/2011 6:13:12 PM : Outperform Start Price: $10.65 DNDN Score: +15.35

Sell off over done

Recs

1
Member Avatar UgolinoII (97.80) Submitted: 8/5/2011 6:45:32 AM : Outperform Start Price: $12.61 DNDN Score: +1.07

for the bounce

Recs

0
Member Avatar Bearywhite (< 20) Submitted: 8/4/2011 9:04:49 PM : Outperform Start Price: $12.20 DNDN Score: +3.60

Short term gains as the panic levels

Featured Broker Partners


Advertisement